Posters

Choroidal thickness as a predictor of geographic atrophy after intravitreal antiangiogenic therapy for neovascular age-related macular degeneration

Poster Details

First Author: K.Montes-Leon COLOMBIA

Co Author(s):    F. Rodriguez-Alvira   M. Ibanez                          

Abstract Details



Purpose:

To determine the choroid thickness as a predictor of geographic atrophy after intravitreal antiangiogenic therapy for neovascular age-related macular degeneration (AMD).

Setting:

To determine the choroid thickness as a predictor of geographic atrophy after intravitreal antiangiogenic therapy for neovascular age-related macular degeneration (AMD).

Methods:

Observational, longitudinal, prospective, non-randomized, cohort trial of patients with neovascular AMD who received intravitreal antiangiogenic therapy (loading dose of three monthly intravitreal injections of ranibizumab0.5 mg or bevacizumab1.25 mg or aflibercept2 mg). Clinical follow-up was performed with spectral domain optical coherence tomography (SD – OCT) twelve months after the intravitreal antiangiogenic therapy. Statistical analysis was performed using nonparametric regression methods and confidence intervals of 95%.

Results:

Sixty-one patients (50.8% women), mean age 75.87 + 9.48 years old and mean disease duration 10.12 + 13.37 months were included with a total of 68 eyes with neovascular AMD with average central foveal thickness (CFT) prior to antiangiogenic therapy 313.59+110.95μm, average central foveal choroidal thickness (CT) pretreatment was 210.80+87.47μm, average LogMAR visual acuity (VA) pretreatment was 0.9+0.6, and average intraocular pressure pretreatment was 15.23+2.61mmHg. Treatment was provided with ranibizumab (14.56%), bevacizumab (15.53%), aflibercept (25.24%) and combined cycles (44.66%). If pre-treatment CT <200um there was significantly lower median CFT post-treatment (252um) when compared to pre-treatment CT >200um with a median of 275um (p = 0.019, U Mann-Whitney test at one tale). In the group with pre-treatment CT <200um, there was statistically significant difference between post-treatment CFT minus pretreatment CFT (median = -53um) than in the group of CT >200um (median = -14um) (p = 0.002, Wilcoxon test).

Conclusions:

Baseline choroidal thickness prior to antiangiogenic therapy is associated to the pre and post-treatment difference of the central foveal thickness. Baseline choroidal thickness is a predictor of geographic atrophy after intravitreal antiangiogenic therapy for neovascular age-related macular degeneration.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy